December 13, 2019 / 8:08 PM / a month ago

Bristol-Myers prevails over Gilead in Yescarta royalty row - Bloomberg Law

Dec 13 (Reuters) - Bristol-Myers Squibb Co won a patent infringement trial against Gilead Sciences Inc’s unit Kite Pharma over cancer immunotherapy Yescarta, Bloomberg Law reported on Friday.

Gilead owes Bristol-Myers $585 million in damages plus a 27.6% running royalty on sales of CAR-T cell therapy Yescarta, the report said, quoting a federal jury in Los Angeles. (bit.ly/2qLvAca) (Reporting by Manojna Maddipatla in Bengaluru; Editing by Shailesh Kuber)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below